Published on 02/12/2025

Dashboards for Model Health: What to Show

In the increasing prevalence of artificial intelligence (AI) and machine learning (ML) in pharmaceutical analytics, ensuring compliance and maintaining operational effectiveness is paramount. As organizations endeavor to incorporate AI/ML models into their Good Practice (GxP) environments, establishing a robust framework for model validation, monitoring, and governance is essential. This article serves as a step-by-step guide on designing and utilizing dashboards for model health, specifically focusing on critical areas such as intended use, data readiness, drift monitoring, and compliance with regulatory standards.

Understanding Dashboards for Model Health

Dashboards are visual interfaces that aggregate and present data to aid in decision-making processes. In the context of model health, a well-designed dashboard should provide a comprehensive view of the performance and status of ML models deployed in laboratories. It is crucial for professionals in the pharmaceutical industry to understand that these dashboards serve multiple purposes: they facilitate monitoring, enable quick identification of issues, and ensure regulatory compliance.

To design an effective dashboard, several key components must be incorporated, each targeting specific aspects of model validation and monitoring. These components include:

• Intended Use and Data Readiness: Clearly define the model’s purpose and ensure the data used aligns with this intended use.
• Bias and Fairness Testing: Implement ongoing assessments for bias and fairness to uphold ethical standards.
• Model Verification and Validation (V&V): Include metrics and results of model V&V to demonstrate compliance.
• Explainability (XAI): Feature elements that provide insights into model decisions.
• Drift Monitoring and Re-Validation: Track model performance over time, identifying any degradation or deviation from expected outcomes.
• Documentation and Audit Trails: Ensure all actions related to the model are documented for regulatory scrutiny.
• AI Governance and Security: Address data integrity and security measures in line with 21 CFR Part 11 and other applicable regulations.

Step 1: Define Your Model’s Intended Use

The first step in creating a dashboard for model health is to comprehend and articulate the intended use of the AI/ML model. This defines how the model will be deployed within the lab environment and sets the stage for data readiness. The intended use should be formalized in documentation and should include any specific claims regarding the model’s purpose.

In accordance with regulatory standards, particularly the guidance from the FDA and EMA, it is crucial to evaluate whether the data falls within the specified parameters of intended use. This involves assessing:

• Target Population: Who will use the model, and in what scenarios?
• Application Scope: What specific tasks or processes will the model assist with?
• Performance Requirements: What benchmarks must the model meet to be deemed effective?

By establishing a clear definition of intended use, practitioners can better curate the required data, ensuring it is relevant and appropriate for the model’s operation.

Step 2: Ensure Data Readiness Curation

Data readiness refers to the process of preparing data so it is suitable for modeling purposes. Proper data curation is essential to guarantee that the input data for AI/ML models is accurate, consistent, and reflective of the intended use.

This step involves several critical tasks:

• Data Collection: Gather data from relevant sources, ensuring that the volume and variety meet the model’s requirements.
• Data Cleaning: Identify and rectify any inaccuracies or missing values in the dataset.
• Data Transformation: Process the data into a suitable format, which may include normalization or encoding of categorical variables.
• Data Validation: Confirm the data meets quality standards and verifies the criteria set in the intended use documentation.

In the context of GxP compliance, it’s critical to maintain thorough documentation of all data curation activities, creating an audit trail that supports future regulatory reviews. This aligns with the requirements outlined in GxP guidelines, including FDA guidance on biologics.

Step 3: Conduct Bias and Fairness Testing

As AI and ML systems are inherently susceptible to biases present in the training data, it is essential to implement rigorous bias and fairness testing as a part of the model health dashboard. The integrity of the data and the model’s output can significantly impact patient safety and treatment outcomes, necessitating a structured approach to these assessments.

The following strategies can help mitigate bias:

• Bias Detection Algorithms: Utilize established statistical methods to identify and quantify potential biases in model predictions.
• Comparative Analysis: Evaluate model performance across different demographic subgroups to ensure fairness.
• Feedback Mechanisms: Set up channels to collect feedback from stakeholders regarding model decisions, adjusting the model as necessary.

Moreover, documenting the outcomes of bias assessments not only enhances transparency but also contributes to a proactive bias management strategy within your organization. This reflects an adherence to ethical considerations and regulatory expectations for EMA compliance.

Step 4: Implement Model Verification and Validation (V&V)

Model verification and validation (V&V) are critical processes in the lifecycle of AI/ML models, ensuring that the models function as intended and meet predefined specifications. Verification assesses whether the model has been built correctly, while validation checks if the right model has been built based on the intended use.

The V&V process should encompass:

• Unit Testing: Test individual components of the model to verify their functionality.
• Integration Testing: Ensure that model components work together as intended.
• System Validation: Validate the complete model system against the intended use and performance requirements.
• Post-Deployment Validation: Continuously monitor the model’s output in real-world applications, adjusting the model as necessary.

Each stage of V&V must be meticulously documented, producing a comprehensive validation report that supports regulatory requirements and collaboration among teams in the laboratory. This aligns with the guidance provided in GAMP 5 for software validation.

Step 5: Incorporate Explainability (XAI)

As AI/ML models become more complex, it is vital to ensure that their decision-making processes are interpretable and transparent. Explainable AI (XAI) addresses this challenge, providing insights into how models arrive at their conclusions. This is particularly important in GxP environments where accountability is paramount.

To effectively implement XAI, the following strategies should be considered:

• Feature Importance Analysis: Highlight the most significant features influencing model predictions.
• Model Interpretation Techniques: Utilize methods like LIME (Local Interpretable Model-agnostic Explanations) to provide explanations for individual predictions.
• Visualizations: Incorporate visual tools that simplify complex model outputs, making them accessible to non-technical stakeholders.

Providing clarity into AI decision processes enhances trust in model outputs and is essential for compliance with regulatory standards, including documentation requirements under 21 CFR Part 11.

Step 6: Establish Drift Monitoring and Re-Validation Mechanisms

Model drift, the phenomenon where a model’s performance deteriorates over time due to changes in the underlying data distribution, poses a significant risk in AI/ML applications. Thus, implementing drift monitoring and re-validation processes is crucial for maintaining model health.

Steps to monitor and manage model drift include:

• Performance Tracking: Regularly track model performance using appropriate metrics, comparing current performance against baseline measures.
• Data Monitoring: Continuously evaluate incoming data for shifts in distributions that could affect model accuracy.
• Scheduled Re-Validation: Establish timeframes for periodic re-validation, ensuring the model remains aligned with intended use and performance expectations.

Documentation of drift monitoring processes and results plays a vital role in compliance and provides an important audit trail for regulatory inspection. Regular reviews help in addressing potential issues proactively, adhering to standards outlined in PIC/S and EMA guidelines.

Step 7: Ensure Documentation and Audit Trails

Documentation serves as the backbone of regulatory compliance. In the context of AI/ML model health, maintaining detailed records of all validation efforts, monitoring activities, and decision-making processes ensures that organizations remain aligned with GxP standards. Proper documentation also safeguards against non-compliance, particularly during inspections.

The documentation must include:

• Model Development Reports: Comprehensive records of the model development lifecycle.
• Validation and Testing Protocols: Documents detailing methods and outcomes of V&V processes.
• Monitoring Reports: Regular updates on model performance and data distributions.
• Change Control Records: Captures any changes made to the model or underlying processes.

Through rigorous documentation practices, pharmaceutical organizations can enhance traceability, supporting regulatory compliance and fostering trust among stakeholders.

Step 8: Establish AI Governance and Security Measures

Ensuring governance and security in AI deployments is paramount for maintaining regulatory compliance and data integrity. This involves implementing measures to protect data and model outputs, as well as establishing governance frameworks guiding model usage and monitoring.

Key governance and security aspects include:

• Data Security Protocols: Implement access controls, encryption, and secure data storage to protect sensitive information.
• Regulatory Compliance Checks: Regularly assess adherence to regulations such as 21 CFR Part 11, adopting best practices for electronic records management.
• Governance Framework: Establish policies and procedures detailing how AI/ML models should be developed, validated, and monitored.

By addressing governance and security concerns proactively, pharmaceutical organizations can further mitigate risks associated with model deployment, ensuring compliance with industry standards and regulations.

Conclusion

In the rapidly evolving field of AI and machine learning within pharmaceuticals, developing comprehensive dashboards for model health is essential for ensuring regulatory compliance and operational effectiveness. By following the steps outlined in this guide, organizations can create systems that not only monitor model performance but also foster transparency, ethics, and accountability. Implementing these practices enables pharmaceutical professionals to embrace innovation while adhering to the rigorous standards necessary for safeguarding public health.